Thus, a prediction of the current studies is that the combined use of inhibitors of HES6 function, androgen withdrawal and strategies for gene re-expression, would synergise in preventing the growth of castration-sensitive prostate cancer. The gene discussed is HES6; the disease is prostate cancer.